Compare BIT & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BIT | ENTA |
|---|---|---|
| Founded | 2013 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 576.9M | 486.3M |
| IPO Year | N/A | 2013 |
| Metric | BIT | ENTA |
|---|---|---|
| Price | $13.21 | $13.47 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $20.40 |
| AVG Volume (30 Days) | 92.4K | ★ 379.3K |
| Earning Date | 01-01-0001 | 02-09-2026 |
| Dividend Yield | ★ 9.36% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $65,324,000.00 |
| Revenue This Year | N/A | $0.99 |
| Revenue Next Year | N/A | $0.19 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $13.65 | $4.09 |
| 52 Week High | $15.97 | $17.15 |
| Indicator | BIT | ENTA |
|---|---|---|
| Relative Strength Index (RSI) | 55.52 | 41.63 |
| Support Level | $13.06 | $14.07 |
| Resistance Level | $13.23 | $13.98 |
| Average True Range (ATR) | 0.09 | 0.95 |
| MACD | 0.01 | -0.39 |
| Stochastic Oscillator | 82.43 | 5.62 |
BlackRock Multi-Sector Income Trust is a closed-end investment management company. It invests on behalf of its clients. The fund's primary investment objective is to provide a high level of current income, with a secondary objective of capital appreciation. The company seeks to achieve its investment objectives by investing, under normal market conditions, a majority of its assets in loan and debt instruments and other investments with similar economic characteristics. Its portfolio consists of Corporate Bonds, Asset-Backed Securities, Preferred Securities, and others.
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.